Logo do repositório
  • Página Inicial(current)
  • Buscar
    Por Data de PublicaçãoPor AutorPor TítuloPor Assunto
  • Tutoriais
  • Documentos
  • Sobre o RI
  • Eventos
    Repositório Institucional da UFRN: 15 anos de conexão com o conhecimento
  • Padrão
  • Amarelo
  • Azul
  • Verde
  • English
  • Português do Brasil
Entrar

SIGAA

  1. Início
  2. Pesquisar por Autor

Navegando por Autor "Queiroz, Jaluza Luana Cravalho de"

Filtrar resultados informando as primeiras letras
Agora exibindo 1 - 1 de 1
  • Resultados por página
  • Opções de Ordenação
  • Nenhuma Miniatura disponível
    Artigo
    Tamarind trypsin inhibitor in chitosan–Whey protein nanoparticles reduces fasting blood glucose levels without compromising Insulinemia: a preclinical study
    (Nutrients, 2019) Morais, Ana Heloneida de Araújo; Matias, Lidia Leonize Rodrigues; Costa, Rafael Oliveira de Araújo; Passos, Thais Souza; Queiroz, Jaluza Luana Cravalho de; Serquiz, Alexandre Coelho; Maciel, Bruna Leal Lima; Santos, Pedro Paulo de Andrade; Camillo, Cristina da Silva; Gonçalves, Catarina; Amado, Izabel Rodriguez; Pastrana, Lorenzo; https://orcid.org/0000-0002-6460-911X
    In vivo studies show the benefits of the trypsin inhibitor isolated from tamarind (Tamarindusindica L.) (TTI) seeds in satiety and obesity. In the present study, TTI nanoencapsulation (ECW) was performed to potentialize the effect of TTI and allow a controlled release in the stomach. The impact on glycemia, insulin, and lipid profile was evaluated in Wistar rats overfed with a high glycemic index diet (HGLI). Characterization of the nanoparticles and in vitro stability in simulated gastrointestinal conditions, monitored by antitrypsin activity and HPLC, was performed. ECW and empty nanoparticles (CW) were administered by gavage, using 12.5 and 10.0 mg/kg, respectively. Both nanoformulations presented a spherical shape and smooth surface, with an average diameter of 117.4 nm (24.1) for ECW and 123.9 nm (11.3) for CW. ECW maintained the antitrypsin activity (95.5%) in the gastric phase, while TTI was completely hydrolyzed. In Wistar rats, the nanoformulations significantly reduced glycemia and HOMA IR, and ECW increased HDL-c compared to CW (p < 0.05).Pancreas histopathology of animals treated with ECW suggested an onset of tissue repair. Thenanoencapsulation provided TTI protection, gradual release in the desired condition, and improvement of biochemical parameters related to carbohydrate metabolism disorders,without compromising insulinemia
Repositório Institucional - UFRN Campus Universitário Lagoa NovaCEP 59078-970 Caixa postal 1524 Natal/RN - BrasilUniversidade Federal do Rio Grande do Norte© Copyright 2025. Todos os direitos reservados.
Contato+55 (84) 3342-2260 - R232Setor de Repositórios Digitaisrepositorio@bczm.ufrn.br
DSpaceIBICT
OasisBR
LAReferencia
Customizado pela CAT - BCZM